Hyperlipidemia in immune thrombocytopenia: a retrospective study

Background Immune thrombocytopenia (ITP) is an autoimmune hemorrhagic disease characterized by low platelet count and bleeding manifestations. However, some patients also suffered from atherosclerosis or even infarction. Apart from activated platelets, lipid metabolism takes a large part in the form...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis journal 2023-10, Vol.21 (1), p.1-102, Article 102
Main Authors: Han, Shouqing, Lu, Hui, Yu, Yafei, Liu, Xinguang, Jing, Fangmiao, Wang, Liang, Zhao, Yajing, Hou, Ming
Format: Article
Language:English
Subjects:
Age
Atherosclerosis
Autoimmune diseases
Bleeding
Blood lipids
Blood platelets
Body mass index
Care and treatment
Cholesterol
Hematology
High density lipoprotein
Hospitals
Hyperlipidemia
Hypertension
Immune thrombocytopenia
Lipid metabolism
Lipids
Metabolic disorders
Metabolic syndrome
Physiological aspects
Regression analysis
Software
Statins
Statistical analysis
Steroids
Thrombocytopenia
Thrombosis
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Immune thrombocytopenia (ITP) is an autoimmune hemorrhagic disease characterized by low platelet count and bleeding manifestations. However, some patients also suffered from atherosclerosis or even infarction. Apart from activated platelets, lipid metabolism takes a large part in the formation of atherosclerosis and metabolic syndrome. The lipid metabolic state in ITP patients is still unknown. Methods We retrospectively reviewed 302 hospitalized ITP patients in our cohort, comparing their blood lipids, bleeding symptoms, metabolic diseases and treatment responses. Results We found a high proportion of ITP patients suffered from hyperlipidemia, and other metabolic diseases including cardiovascular or cerebral atherosclerosis or infarction, hypertension, and type 2 diabetes. Hyperlipidemia was associated with severe bleeding and treatment refractoriness in ITP. Statins could alleviate thrombocytopenia and bleeding severity, and facilitate ITP treatment, while improving hyperlipidemia in ITP patients. Conclusions Our present study demonstrated that lipid metabolism might play an indispensable role in ITP pathogenesis and development. Keywords: Immune thrombocytopenia, Bleeding, Lipid metabolism, Statins
ISSN:1477-9560
1477-9560
DOI:10.1186/s12959-023-00545-9